C4 Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2021 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: C4 Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q3 2024.
C4 Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 54.1 %, a 1.58% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	54.1	+0.84	+1.58%	Sep 30, 2024
Q2 2024	53.9	+3.18	+6.27%	Jun 30, 2024
Q1 2024	55.4	+8.78	+18.8%	Mar 31, 2024
Q4 2023	54.5	+10.2	+22.9%	Dec 31, 2023
Q3 2023	53.3	+13.8	+35%	Sep 30, 2023
Q2 2023	50.7	+15.7	+44.6%	Jun 30, 2023
Q1 2023	46.6	+15.5	+49.6%	Mar 31, 2023
Q4 2022	44.3	+13.8	+45.1%	Dec 31, 2022
Q3 2022	39.5	+6.32	+19.1%	Sep 30, 2022
Q2 2022	35.1	-23.3	-40%	Jun 30, 2022
Q1 2022	31.2			Mar 31, 2022
Q4 2021	30.6			Dec 31, 2021
Q3 2021	33.2			Sep 30, 2021
Q2 2021	58.4			Jun 30, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.